Published • loading... • Updated
High-Precision Base-Editing Therapy Demonstrates Durable VOC-Free Efficacy and Favorable Safety in Sickle Cell Disease
The patient showed rapid blood recovery and no product-related adverse events as Correctseq said the therapy met its primary efficacy endpoint.
- On Tuesday, June 2, 2026, CorrectSequence Therapeutics announced that the first sickle cell disease patient treated in China with CS-206 remained free of VOCs for more than 15 months following engraftment, achieving the primary efficacy endpoint.
- Sickle cell disease, a hereditary hemoglobin disorder affecting around 300,000 babies born annually, causes chronic anemia and recurrent pain crises; the 21-year-old patient from Nigeria had experienced recurrent severe VOCs prior to treatment.
- Correctseq utilizes a proprietary transformer Base Editor to edit the HBG1 promoter region, a precise method that avoids DNA double-strand breaks and offers a safer alternative to CRISPR-based gene-editing therapies.
- Within one month, HbF levels increased significantly while HbS levels declined; beginning at Month 3, the HbF-to-HbS ratio stabilized at approximately 6:4, with neutrophil engraftment achieved by Day 13.
- Global recruitment for the CS-206 investigator-initiated trial is currently ongoing, while Correctseq's CS-101 has successfully cured more than ten thalassemia patients across China, Laos, Malaysia, and Pakistan.
Insights by Ground AI
18 Articles
18 Articles
Coverage Details
Total News Sources18
Leaning Left5Leaning Right3Center5Last UpdatedBias Distribution39% Left, 38% Center
Bias Distribution
- 39% of the sources lean Left, 38% of the sources are Center
39% Left
L 39%
C 38%
R 23%
Factuality
To view factuality data please Upgrade to Premium
